Giredestrant
Giredestrant (GDC-9545), a non-steroidal estrogen receptor (ER) ligand, is an orally active and selective ER antagonist. Giredestrant potently competes with Estradiol for binding and induces a conformational change within the ER ligand binding domain. Giredestrant has anti-tumor activity[1].
Product Specifications
CAS Number
1953133-47-5
Product Name Alternative
GDC-9545; RG6171
UNSPSC
12352005
Hazard Statement
H302, H315, H319
Target
Estrogen Receptor/ERR
Type
Reference compound
Related Pathways
Vitamin D Related/Nuclear Receptor
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/giredestrant.html
Purity
99.52
Solubility
DMSO : 50 mg/mL (ultrasonic)
Smiles
OCC(F)(F)CN([C@@H]1C2=C(F)C=C(NC3CN(CCCF)C3)C=C2F)[C@H](C)CC4=C1NC5=C4C=CC=C5
Molecular Formula
C27H31F5N4O
Molecular Weight
522.55
Precautions
H302, H315, H319
References & Citations
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 3
Isoform
Estrogen receptor
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
PSA (Prostate Specific Antigen) (A67-B/E3), CF488A conjugate, 0.1mg/mL
Tropomyosin 2 (TPM2) (NM_213674) Human Over-expression Lysate
